News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
Uniswap’s $591mln burn sparks a deflation loop – UNI at $7.2 ONLY IF…
AMBCrypto·2025/12/28 16:03
AI Flags Bitcoin Supply Shock as Exchange Reserves Hit New Lows
The Bitcoin News·2025/12/28 15:27
Bitcoin at a Crossroads: Can BTC Break Above the $90,000 Resistance?
The Bitcoin News·2025/12/28 15:24
Bitcoin News: Record $24 Billion Options Expiry Could Mark a Turning Point for BTC
The Bitcoin News·2025/12/28 14:51
Standard Chartered Cuts 2026 Bitcoin Forecast in Half — But Remains Long-Term Bullish
The Bitcoin News·2025/12/28 14:33
The next crypto winter is coming? Crypto Google searches crash to 1-year low – Kriptoworld.com
Kriptoworld·2025/12/28 14:18
Orexn Connects Crypto Launchpad with zkSync Through KaratDAO Partnership
BlockchainReporter·2025/12/28 14:15
Ethereum’s 2026 roadmap includes this validator risk that’s bigger than you think
CryptoSlate·2025/12/28 14:12
Top Presale Narrative for 2025: IPO Genie’s Sponsorship Visibility Can Drive Early Adoption
BlockchainReporter·2025/12/28 13:12
SUI faces $80 mln unlock as sellers step in: Can bulls defend key resistance?
AMBCrypto·2025/12/28 12:03
Flash
12:56
Spot Gold Drops $14 in Short-Term Spot gold has fallen $14 in the short term, declining over 1.00% during the day, currently reported at $4133.10 per ounce. (Jin Shi)
12:51
Vivos (OTC market code: RDGL) has received Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) and will initiate a human clinical feasibility study of its Radiogel® Precision Radionuclide Therapy™.This approval marks a key step forward for the clinical application of this innovative therapy, allowing the company to begin initial safety and feasibility assessments in humans. The Radiogel® technology is designed to enable precise radiation treatment within tumors and is expected to provide a new treatment option for cancer patients. The approved clinical study will collect essential data to lay the foundation for larger-scale clinical trials in the future.
12:51
Anixa Biosciences announced that in its clinical trial of CAR-T cell therapy, no dose-limiting toxicities were observed up to the previously established 3x10⁶/kg dose level.This positive safety data lays the foundation for further exploration of higher doses and demonstrates the potential of this therapy in terms of patient tolerability.
News